New Alzheimer's pill takes first step in human safety trial
NCT ID NCT06786676
First seen May 13, 2026 · Last updated May 19, 2026 · Updated 4 times
Summary
This early-stage study tests an experimental oral drug called AS-S603, designed to break down protein clumps linked to Alzheimer's disease. The trial involves 88 healthy adults and elderly volunteers in Korea and Caucasian participants to check the drug's safety and how the body processes it. No treatment benefit is expected; the goal is to gather safety data before testing in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital Clinical Trial Center
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.